Capricor Therapeutics Announces FDA's Committee Votes That Available Evidence For Deramiocel Did Not Support Effectiveness To Treat Cardiomyopathy In Patients With Duchenne Muscular Dystrophy

뉴스 본문을 불러오고 있어요.

Capricor Therapeutics Announces FDA's Committee Votes That Available Evidence For Deramiocel Did Not Support Effectiveness To Treat Cardiomyopathy In Patients With Duchenne Muscular Dystrophy | 웨이프 WAPE

Capricor Therapeutics Announces FDA's Committee Votes That Available Evidence For Deramiocel Did Not Support Effectiveness To Treat Cardiomyopathy In Patients With Duchenne Muscular Dystrophy

기사 요약

관련 종목

댓글 —